Kanabo Group plc (LSE: KNB), a digital health company that specialises in patient-focused services and medicinal cannabis, announced on Tuesday that it has extended its contract with a prominent UK health and beauty retail and e-pharmacy services provider.
Originally partnering in 2019, the extension, facilitated through Kanabo's telehealth platform, The GP Service, grants the retailer continued access to video consultations and prescription services for another 12 months. The extension expands Kanabo's patient base, providing faster and more accessible healthcare through over 4,000 UK pharmacies.
The company is dedicated to transforming patient care through its digital health platform, offering regulated medicinal cannabis-derived formulations and inhalation devices. Its NHS-approved telehealth platform, The GP Service, provides video consultations, online prescriptions and primary care services, with additional offerings like Treat It, an online clinic focusing on chronic pain management. Kanabo's comprehensive approach includes a subsidiary, Kanabo Agritec Ltd, supporting cannabis businesses in cultivation for high-quality raw materials.
Hologic acquires Gynesonics for USD350m
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Microtech commences human clinical trial of microsensor platform for heart failure
Humacyte Global receives approval from FDA for Symvess
Defense Diagnostics launches DEFENT ONE All-In-One Fentanyl Detection Device in US
HeartBeam secures FDA clearance for innovative at-home heart monitoring device
Eli Lilly to expand Wisconsin facility
EQUASHIELD partners with Pharmacy Stars
Integrum AB introduces new service initiative in US
GC Biopharma and Novel Pharma report first patient dosed in multinational trial of GC1130A
Abbott launches first patient procedures with investigational TAVI system
SHL Medical to establish tooling and automation sub-group
Epigenic Therapeutics receives New Zealand approval for EPI-003 clinical trial
GRAIL reports first patient tested with blood-based assay in TROPION-Lung12 Phase 3 study
SciBase's Nevisense shows promise in monitoring atopic dermatitis treatment